Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Complex
Launched by AESCULAP AG · Mar 15, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and performance of a medical device called Ennovate® Complex, which is used to treat various types of spinal deformities, such as hyperkyphosis (excessive curvature of the upper back), hyperlordosis (excessive curvature of the lower back), congenital scoliosis (spinal deformities present at birth), neuromuscular scoliosis (caused by conditions affecting the nerves and muscles), and idiopathic scoliosis (curvature of the spine with no known cause). The trial is currently recruiting participants from different centers and is focused on collecting data from patients who have received this treatment.
To be eligible for the study, participants must be at least 18 years old and provide consent to have their clinical and imaging results documented. For younger patients, a parent or legal guardian must also give consent. Participants should not be pregnant and should be willing to attend follow-up examinations. Throughout the study, participants can expect to help researchers gather important information that could improve the understanding of the Ennovate® Complex device's effectiveness and safety. It's important to note that this study is observational, meaning that patients will not receive any specific treatments as part of the trial; rather, the focus is on collecting information about their experiences and outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent in the documentation of clinical and radiological results of patients who are minimum 18 years old
- • Informed consent in the documentation of clinical and radiological results of patients AND legal representative (parent) for patients who are younger than 18
- • Patient's indication according to IFU
- • Patient is not pregnant
- Exclusion Criteria:
- • Patient's clear unability or unwillingness to participate in follow-up examinations
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brno, , Czechia
Kuala Lumpur, , Malaysia
Patients applied
Trial Officials
Mohd Hisam, Prof. Dr.
Principal Investigator
Hospital Universiti Kebangsaan Malaysia (HUKM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials